Figure 4 | Scientific Reports

Figure 4

From: A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

Figure 4The alternative text for this image may have been generated using AI.

Summary of Anti-S IgG against Omicron BA.1 and Omicron BA.5 at each visit (Per protocol population). GMEU Geometric Mean ELISA Unit. For each study vaccine, the GMEU of Anti-S IgG and 95% CI were calculated by transforming to the original scale of log10-transformed mean and its two-sided 95% CI limits at each visit.

Back to article page